Cleaning Validation Capabilities
Kymanox utilizes a controlled, quality-driven process that manages risk and ultimately ensures a safe and effective product for the patient.
Meet our Cleaning Validation Solutions Experts
Michelle Frakes, PhD
DIRECTOR, BUSINESS SOLUTIONS AND MARKETING


Helpful Links
Here are some of our favorite resources on this topic
Markets That Benefit from Our Cleaning Validation Solutions
Combination Products
Our experts understand the interaction between devices and drug products. Our experience includes injectables, nasal, respiratory, and more.
Biologics & Cell and Gene Therapy Services
We understand why “the product is the process” and how to implement solutions to your unique challenges.




The Kymanox Difference
At Kymanox we are more than consultants. We are partners with our clients and create custom solutions that meet each client’s unique needs.

Proven Broad Expertise
Our team of experts is focused on life sciences with extensive experience across drug and device development. No matter your challenge, we can help you conquer it.

Flexibility & Agility
At Kymanox, we make it easy for clients to get the solutions they need, when they need it. Clients tell us our flexibility is one of the key reasons they keep coming back.

Dynamic Project Management
A personalized approach to project management that combines your needs with our proven tools and expertise to create a custom solution for your project.
Frequently Asked Cleaning Validation Questions (FAQs)
Where do you start when implementing a cleaning validation process?
A risk assessment is necessary to assess the cleaning validation strategy and the level of validation required for each cleaning procedure. Some criteria that may be considered, if applicable, in the risk assessment are as follows. This list is not considered an all-inclusive list and additional criteria may be applicable for a specific cleaning procedure.
- Solubility of process soils
- Dosage levels, toxicity, potency of process soils
- Equipment design, construction, surface material of construction
- Dedicated vs. multi product equipment
- Non-sterile vs. sterile processing
- Location of equipment step within overall process
- Manufacturing campaigns
- Batch size and possible changeovers
- Processing time
- Cleaning procedure (manual, semi-automated, fully automated)
- Cleaning intervals
- Equipment holding times (dirty and clean)
- Acceptance criteria
- Number of products covered by the cleaning procedure
- Cleaning agent residuals
- Subsequent equipment sterilization
- Equipment soiling (artificial soiling vs. actual processing)
- Equipment loading
- First vs. re-validation
Are there any pre-requisites to consider before beginning a cleaning validation process?
Prior to initiating formal cleaning validation, several activities must be completed. Equipment qualification activities for the associated equipment must have been successfully completed. For equipment that is cleaned with a spray device, coverage studies must be completed with acceptable results. For equipment cleaned with automated cycles, the cleaning cycle automation must be qualified. The cleaning procedure for the equipment must be documented and approved. Note: Cleaning procedures may need to be revised at the completion of cleaning validation activities to incorporate any recommendations from the validation effort. Also, analytical assays used during the validation study and the instruments used to perform these assays must be validated.
What types of changes require re-validation of a cleaning process?
Changes resulting from new regulatory guidance, process improvements or new products can affect the validated status of cleaning cycles. These changes can include changes to validated cycle parameters, changes to procedures or hold times, software upgrades, new loads or load configurations, changes to equipment or piping, changes to products, or changes to cleaning agents. The impact will need to be assessed for each individual change.
Read the Latest at Kymanox
Kymanox Acquires EU Based Anteris Medical and Anteris Helvetia
Leveraging the well-respected anteris brand and team, this acquisition extends Kymanox’s capabilities and geographic reach with a strong European presence
Friday, 03 February 2023
Morrisville, North Carolina, USA and Holzkirchen, Germany an...
Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen
Kymanox Executive Advisors (KEAs) Mathias Romacker, Fran DeGrazio, and Paul Jansen sit down with Guy Furness to discuss what has driven Kymanox's rapid rise in the drug delivery space and what makes the consulting company's model so successful, as well...
Growing Happy Cells: Bioreactor Optimization
Biologics, including cell and gene therapies, have become a hot topic in the pharmaceutical industry as their therapeutic applications expand. Challenges of developing biologic drug products include scale-up for commercial manufacturing and production ...